Earnings Summary

SIGILON THERAPEUTICS INC’s revenue jumped 53.49% since last year same period to $4.86Mn in the Q1 2023. On a quarterly growth basis, SIGILON THERAPEUTICS INC has generated 83.74% jump in its revenue since last 3-months.

SIGILON THERAPEUTICS INC’s net profit jumped 45.82% since last year same period to $-7.51Mn in the Q1 2023. On a quarterly growth basis, SIGILON THERAPEUTICS INC has generated -12.33% fall in its net profits since last 3-months.

SIGILON THERAPEUTICS INC’s net profit margin jumped 64.7% since last year same period to -154.57% in the Q1 2023. On a quarterly growth basis, SIGILON THERAPEUTICS INC has generated 38.87% jump in its net profit margins since last 3-months.

SIGILON THERAPEUTICS INC’s earning per share (EPS) estimates for the current quarter stand at -0.39 - a 7.14% jump from last quarter’s estimates.

SIGILON THERAPEUTICS INC’s earning per share (EPS) estimates for the current year stand at -0.39.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. SIGILON THERAPEUTICS INC’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. SIGILON THERAPEUTICS INC’s return on equity (ROE) stands at -0.76.